<--- Back to Details
First PageDocument Content
European Commission / Cancer organizations / Joint Research Centre / Cancer registry / Ispra / Epidemiology of cancer / Institute for Health and Consumer Protection / International Agency for Research on Cancer / Breast cancer / Medicine / Science and technology in Europe / Oncology
Date: 2013-08-01 11:17:04
European Commission
Cancer organizations
Joint Research Centre
Cancer registry
Ispra
Epidemiology of cancer
Institute for Health and Consumer Protection
International Agency for Research on Cancer
Breast cancer
Medicine
Science and technology in Europe
Oncology

ENCR  European Network of Cancer Registries 1 Highlights 2 Focus

Add to Reading List

Source URL: www.encr.eu

Download Document from Source Website

File Size: 1,37 MB

Share Document on Facebook

Similar Documents

Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction

DocID: 1vq0d - View Document

Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser

DocID: 1vpNA - View Document

Frequently Asked Questions: Trainees seeking a PhD education in Cancer Biology or a related area with a focus on Breast Cancer Health Disparities. 1. What is the Komen Graduate Training in Disparities Research Grant (GT

DocID: 1voV1 - View Document

_____________________________________________________________ What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014]

DocID: 1vlqg - View Document

Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin

DocID: 1vl9e - View Document